select trial semaglutide cardiovascular outcomes without diabetes 2023 A Skeptical Take of for Cardiac Protection SELECT Trial

scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight Results: Primary outcome (change in KCCQ-CSS score): Semaglutide +13.7, Placebo +6.4 (p 20 g (women) 30 g (men) Hepatic decompensation AST or ALT level 5 X ULN eGFR 9.5%

They essentially tell your body it's full, reducing cravings and potentially speeding up your metabolism

Prescription weight loss medications can effectively complement lifestyle changes by regulating hunger signals and managing energy storage

Most weight loss occurs in the first 24 to 36 weeks, with maintenance thereafter

They provide ongoing monitoring of your health and progress, adjusting your treatment plan as necessary

Minor side effects often happen when starting the program but usually fade over time